IDEXX Laboratories, Inc. (IDXX) Director Sells $812,750.00 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director William T. End sold 5,000 shares of the stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $162.55, for a total transaction of $812,750.00. Following the transaction, the director now owns 45,256 shares in the company, valued at $7,356,362.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

IDEXX Laboratories, Inc. (IDXX) traded up 0.09% during trading on Friday, hitting $160.71. 1,120,919 shares of the stock traded hands. IDEXX Laboratories, Inc. has a 52 week low of $85.98 and a 52 week high of $173.01. The firm’s 50-day moving average is $164.46 and its 200 day moving average is $143.85. The stock has a market cap of $14.16 billion, a P/E ratio of 59.54 and a beta of 0.53.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Friday, April 28th. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.16. IDEXX Laboratories had a negative return on equity of 706.91% and a net margin of 13.47%. The business had revenue of $462 million during the quarter, compared to analyst estimates of $455.10 million. During the same period in the previous year, the firm earned $0.51 EPS. IDEXX Laboratories’s quarterly revenue was up 10.7% compared to the same quarter last year. Equities research analysts forecast that IDEXX Laboratories, Inc. will post $3.05 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Director Sells $812,750.00 in Stock” was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/06/16/william-t-end-sells-5000-shares-of-idexx-laboratories-inc-idxx-stock-updated-updated.html.

Institutional investors have recently added to or reduced their stakes in the company. Advantus Capital Management Inc increased its position in IDEXX Laboratories by 0.9% in the third quarter. Advantus Capital Management Inc now owns 10,943 shares of the company’s stock worth $1,234,000 after buying an additional 100 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in IDEXX Laboratories by 108.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,161 shares of the company’s stock worth $2,385,000 after buying an additional 11,031 shares during the period. Hartford Investment Management Co. purchased a new position in IDEXX Laboratories during the third quarter worth $211,000. KCG Holdings Inc. increased its position in IDEXX Laboratories by 113.4% in the third quarter. KCG Holdings Inc. now owns 6,787 shares of the company’s stock worth $765,000 after buying an additional 3,606 shares during the period. Finally, Nomura Asset Management Co. Ltd. increased its position in IDEXX Laboratories by 4.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 9,890 shares of the company’s stock worth $1,115,000 after buying an additional 440 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

IDXX has been the topic of a number of recent research reports. BidaskClub downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Canaccord Genuity restated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research report on Tuesday. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $177.00 price target on the stock in a research report on Tuesday. Finally, Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $150.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, May 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. IDEXX Laboratories presently has a consensus rating of “Hold” and a consensus price target of $165.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply